DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly ALKS 2680, is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for NT1,...
Latest News
DUBLIN, Oct. 23, 2023 — Alkermes plc (Nasdaq: ALKS) announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability,...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place Sept. 5-10, 2025 in Singapore, and in an investor webcast presentation hosted by the company. Alixorexton, formerly referred to as ALKS...
Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented DUBLIN, Ireland — Alkermes plc (Nasdaq:...
CAMBRIDGE, Mass. — Alkeus Pharmaceuticals, Inc. today announced the presentation of interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic while on therapy ranging between two and six years. The study update was presented during the...
European Myasthenia Gravis Day will make it to the calendar for the very first time on 2 June 2023. A symbolic date that will shine the light on this neuromuscular autoimmune disease that affects between 56,000 up to almost 100.000 people in Europe1. This day, initiated by the 'All United for MG'2 coalition which unites patient associations and representatives from seven countries across Europe, aims to raise awareness of the disease and its consequences for patients and their caregivers amongst the general public, medical professionals and the European institutions.
SEATTLE and SAN RAFAEL, Calif. – The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system. BioMarin will receive an exclusive license to each program...
Seattle, WA — With pediatric inflammatory bowel disease (IBD) diagnoses on the rise globally, a clinical trial in Seattle aims to transform treatment approaches through deep molecular profiling. Recruitment has begun for the Seattle STRIDE study, a joint effort by Seattle Children’s Research Institute and the Allen Institute for Immunology....
Chicago, Illinois – Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology today announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized muscle-invasive urothelial...
SOUTH SAN FRANCISCO, Calif. — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases, announced that it has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical...